XML 24 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Statements of Changes in Members' Equity (Brooklyn ImmunoTherapeutics, LLC) - USD ($)
Series D Preferred Stock [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Series C Preferred Stock [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Series B Preferred Stock [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Series A Preferred Stock [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Common Stock [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Common Stock [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Successor [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Additional Paid-In Capital [Member]
Subscriptions Receivable, Related Parties [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Accumulated Deficit [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Accumulated Deficit [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Successor [Member]
Accumulated Deficit [Member]
Total Stockholder's Deficiency [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Total Stockholder's Deficiency [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Successor [Member]
Total Stockholder's Deficiency [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Class A Membership Units [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Successor [Member]
Class A Membership Units [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Class B Membership Units [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Successor [Member]
Class B Membership Units [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Class C Membership Units [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Successor [Member]
Class C Membership Units [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Common Stock [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Accumulated Deficit [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Predecessor [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Successor [Member]
Brooklyn Immunotherapeutics, LLC [Member]
Total
Balance at Dec. 31, 2017 $ 35,400 $ 40,461 $ 35 $ 141 $ 7,968 $ 13,000 $ 179,148,961 $ 134,752,000 $ (88,663) $ (187,130,857) $ (129,119,000) $ (7,986,554)       $ 5,536,000
Balance, shares at Dec. 31, 2017 35,400,669 40,460,713 35,016 140,639 7,968,224   2,521,000                                          
Issuance of common stock upon exchange of preferred stock $ (40,461) $ (35) $ (141) $ 16,772     (106,536,946)   106,560,811                                
Issuance of common stock upon exchange of preferred stock, shares (40,460,713) (35,016) (140,639) 16,771,866                                              
Net loss     (16,098,602)   (16,098,602) $ (16,098,602)      
Balance at Nov. 05, 2018 $ 35,400 $ 24,740   72,612,015   (88,663) (96,668,648)   (24,085,156) 6,482,005 6,482,005        
Balance, shares at Nov. 05, 2018 35,400,669 24,740,090                                              
Balance at Dec. 31, 2017 $ 35,400 $ 40,461 $ 35 $ 141 $ 7,968 $ 13,000 179,148,961 134,752,000 (88,663) (187,130,857) (129,119,000) (7,986,554)       5,536,000
Balance, shares at Dec. 31, 2017 35,400,669 40,460,713 35,016 140,639 7,968,224   2,521,000                                          
Net loss                     (259,000)                             (259,000)
Balance at Dec. 31, 2018           15,248 $ 14,000   136,552,000     (2,004,472) (129,394,000)   10,369,706 10,369,700 9,958,930 9,958,930 1,400,000 1,400,000 1,000,000 1,000,000 15,248 (2,004,472)     $ 10,369,706 6,917,000
Balance, shares at Dec. 31, 2018             2,875,000                                          
Balance at Nov. 05, 2018 $ 35,400 $ 24,740   $ 72,612,015   $ (88,663) $ (96,668,648)   $ (24,085,156) 6,482,005 6,482,005        
Balance, shares at Nov. 05, 2018 35,400,669 24,740,090                                              
Stock based compensation: Amortization of restricted common units           15,248               15,248                    
Stock based compensation: Issuance of membership units for purchase of IRX                         2,400,000     1,400,000   1,000,000              
Stock based compensation: Membership units issued in exchange for services                         5,000 5,000        
Stock based compensation: Sale of members' equity                         1,955,579   1,955,579                  
Stock based compensation: Members' equity exchanged for loans payable and interest                         1,516,346   1,516,346                  
Net loss                     (2,004,472)     (2,004,472)                    
Balance at Dec. 31, 2018           15,248 $ 14,000   136,552,000     (2,004,472) (129,394,000)   10,369,706 10,369,700 9,958,930 9,958,930 1,400,000 1,400,000 1,000,000 1,000,000 15,248 (2,004,472)     10,369,706 6,917,000
Balance, shares at Dec. 31, 2018             2,875,000                                          
Stock based compensation: Amortization of restricted common units                               45,744       45,744        
Stock based compensation: Issuance of membership units for purchase of IRX                                            
Stock based compensation: Membership units issued in exchange for services                                            
Stock based compensation: Sale of members' equity                               5,080,500   5,080,500            
Stock based compensation: Members' equity exchanged for loans payable and interest                                            
Net loss                     (403,000)     (4,123,578)       (4,123,578)     (4,123,578) (403,000)
Balance at Jun. 30, 2019             $ 14,000   136,648,000       (129,805,000)     11,372,372   15,039,430   1,400,000   1,000,000 60,992 (6,128,050)       6,667,000
Balance, shares at Jun. 30, 2019             2,882,000                                          
Balance at Dec. 31, 2018           15,248 $ 14,000   136,552,000     (2,004,472) (129,394,000)   10,369,706 10,369,700 9,958,930 9,958,930 1,400,000 1,400,000 1,000,000 1,000,000 15,248 (2,004,472)     10,369,706 6,917,000
Balance, shares at Dec. 31, 2018             2,875,000                                          
Stock based compensation: Amortization of restricted common units           91,689               91,689        
Stock based compensation: Sale of members' equity                         8,218,762   8,218,762                  
Net loss                 (8,937,054) (2,047,000)   (8,937,054)               $ (8,937,054) 8,937,054 (2,047,000)
Balance at Dec. 31, 2019           106,937 $ 14,000   136,721,000     (10,941,526) (131,457,000)   9,743,103 9,743,103 18,177,692 18,177,692 1,400,000 1,400,000 1,000,000 1,000,000 106,937 (10,941,526)     9,743,103 5,091,000
Balance, shares at Dec. 31, 2019             2,901,000                                          
Balance at Mar. 31, 2019             $ 14,000   136,606,000       (129,707,000)                             6,691,000
Balance, shares at Mar. 31, 2019             2,878,000                                          
Net loss                     (90,000)                             (90,000)
Balance at Jun. 30, 2019             $ 14,000   136,648,000       (129,805,000)     11,372,372   15,039,430   1,400,000   1,000,000 60,992 (6,128,050)       6,667,000
Balance, shares at Jun. 30, 2019             2,882,000                                          
Balance at Dec. 31, 2019           $ 106,937 $ 14,000   136,721,000     $ (10,941,526) (131,457,000)   $ 9,743,103 9,743,103 $ 18,177,692 18,177,692 $ 1,400,000 1,400,000 $ 1,000,000 1,000,000 106,937 (10,941,526)     9,743,103 5,091,000
Balance, shares at Dec. 31, 2019             2,901,000                                          
Stock based compensation: Amortization of restricted common units                               45,468       45,468        
Stock based compensation: Sale of members' equity                               5,024,313   5,024,313            
Net loss                     (3,241,000)     (3,052,658)       (3,052,658)     (3,052,658) (3,241,000)
Balance at Jun. 30, 2020             $ 15,000   136,837,000       (134,706,000)     11,760,226   23,202,005   1,400,000   1,000,000 152,405 (13,994,184)     11,760,226 1,931,000
Balance, shares at Jun. 30, 2020             2,938,000                                          
Balance at Mar. 31, 2020             $ 15,000   136,800,000       (132,675,000)                             3,849,000
Balance, shares at Mar. 31, 2020             2,926,000                                          
Net loss                     (2,023,000)                             (2,023,000)
Balance at Jun. 30, 2020             $ 15,000   $ 136,837,000       $ (134,706,000)     $ 11,760,226   $ 23,202,005   $ 1,400,000   $ 1,000,000 $ 152,405 $ (13,994,184)     $ 11,760,226 $ 1,931,000
Balance, shares at Jun. 30, 2020             2,938,000